Company ProfilePremium

Thirumalai Chemicals Limited

Company Profile Analysis

Ticker: TIRUMALCHM.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
Thirumalai Chemicals Limited - Company showcase

Year Founded & Workforce

1944

477 Employees

Thirumalai Chemicals Limited logo

Thirumalai Chemicals Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Thirumalai Chemicals Limited Overview

Thirumalai Chemicals is a five-decade-old Indian producer of phthalic anhydride (PAN) and its derivatives, and of maleic-anhydride-based food acids (malic and fumaric acid). It is India's second-largest PAN producer behind I G Petrochemicals, describes itself as among the world's top three PAN manufacturers, the largest fumaric-acid producer in India, and the largest maleic anhydride (MAN) producer in Southeast Asia through its Malaysian subsidiary. Historically a cash-generative, near-debt-free commodity chemicals franchise (FY2022 consolidated PAT of INR 281 Cr), TCL has since FY2023 undertaken a transformational, largely debt-funded investment cycle: a large PAN/fumaric expansion at Dahej, Gujarat, and a greenfield MAN and food-acids complex in New Martinsville, West Virginia, now budgeted at USD 340 million. The combination of compressed PAN–orthoxylene spreads, idle Malaysian capacity and US project cost overruns has produced three consecutive loss-making years, a sharply higher leverage profile, covenant waivers and five ICRA downgrades since May 2025. The equity story is now a binary bet on US commissioning (targeted December 2026) and balance-sheet repair.


What the company does

Thirumalai Chemicals manufactures and sells organic chemicals in two broadly related value chains:

  1. Phthalic anhydride chain (bulk/commodity): PAN is produced by catalytic oxidation of ortho-xylene (OX) at Ranipet (Tamil Nadu) and at Dahej (Gujarat, via subsidiary TCL Intermediates Pvt Ltd). PAN is sold to plasticiser makers (PVC cables, flooring, films), unsaturated polyester resin (UPR) producers (fibre-reinforced plastics), alkyd-resin/paint manufacturers, and copper phthalocyanine (CPC) pigment makers. Downstream PAN derivatives include diethyl phthalate (DEP), phthalate esters and phthalimide (PID).

  2. Maleic anhydride and food-acid chain (specialty): MAN is produced from butane (Malaysia; US under commissioning). MAN is the feedstock for malic acid and fumaric acid, which TCL sells in food, beverage, confectionery, bakery, animal feed, pharmaceutical (fumaric acid as API), personal-care and industrial (UPR, alkyd resin, inks) applications. TCL produces both food-grade and pharma-grade malic acid at Ranipet.

Per the FY26 Annual Report, revenue mix is approximately 84% bulk commodity and 16% specialty chemicals.

A secondary capability is TCL Technology & Engineering (TCL-TE), an in-house division that designs, fabricates and supplies "ready-to-start-up" modular process plants and skids. TCL-TE built the modules for the West Virginia project. TCL also historically generated wind power in Tamil Nadu; four windmills are being sold (Aug 2026).

Company's own description (paraphrased from FY2025-26 Annual Report)

The company presents itself as a globally integrated specialty chemicals group that evolved from a single PAN plant at Ranipet into a multi-product, multi-geography enterprise operating in India, Malaysia and the United States, with more than 350 customers across roughly 60 countries. It emphasises that its products go into everyday goods — paints, cable plasticisers, beverage acidulants and pharmaceutical ingredients — and that a key differentiator is the ability to span both industrial-grade and food-grade production within an integrated manufacturing model. Management highlights energy self-sufficiency (over 90% of PAN-operations energy from recovered process heat), zero liquid discharge at Ranipet, and a long-term, discipline-first culture rather than aggressive diversification.

Business and revenue model

DimensionCharacterisation
Revenue model~100% product sales (manufactured chemicals). No subscription or licensing revenue disclosed. Engineering (TCL-TE) is primarily captive. Wind-power income historically immaterial (power segment de-recognised as reportable in 2018)
PricingSpot and contract pricing; ICRA notes medium- to long-term contracts with many customers, but realisations track regional PAN supply–demand and OX costs
Key inputOrtho-xylene, sourced under a long-standing relationship with Reliance Industries on an "assured offtake model" (ICRA); butane for MAN (Malaysia, US); MAN for food acids; ethanol for DEP
Value-chain positionMid-stream intermediate producer: buys petrochemical feedstock, sells intermediates to formulators/converters. Limited product differentiation in PAN; more differentiation (food/pharma grades, certifications) in food acids
Customer typesPlasticiser and resin manufacturers, paint and pigment makers, food and beverage processors, pharmaceutical companies, animal-feed producers, personal-care/fragrance formulators (DEP)
End-marketsConstruction/infrastructure, automotive, paints and coatings, food and beverage, pharmaceuticals, personal care (ICRA, Jun 2026)
Geographic salesFY26: ~90% India, ~10% exports (Annual Report); export mix Europe 43%, North America 25%, Asia 19%, Africa 13%

Independent characterisation

TCL is best understood as a spread business with an embedded growth option. The core Indian PAN franchise earns the PAN–OX spread, which is set largely by Chinese and Korean supply and by anti-dumping protection in India; when spreads are healthy (FY2022) the business generates 20%+ EBITDA margins and strong free cash flow, and when spreads compress (FY2024–FY2026) margins collapse to low single digits or negative. The food-acids business is structurally more attractive — higher value, sticky regulated customers — but it is small relative to PAN and its MAN feedstock economics have been undermined by Chinese oversupply, which has rendered the Malaysian MAN plant largely non-operational. The West Virginia project is a strategic attempt to relocate the higher-value MAN/food-acids chain into a tariff-protected, under-supplied North American market with advantaged shale-gas butane. The problem is that it has been financed predominantly with debt at the same time the core PAN cash engine stalled, producing a classic capex-cycle squeeze.

Strategy

Stated strategy (FY2025-26 Annual Report themes, paraphrased)

The FY26 report is themed around "Growing from Strength to Strength", built on three pillars — Expansion (measured growth across India, Malaysia and the US, staying close to served markets), Innovation/process discipline (continuous improvement of processes, efficiency and quality), and Transformation (becoming more agile, integrated and aligned with a changing global environment). The Chairman's stated near-term priorities are to improve EBITDA through higher volumes and better realisations, keep tight control of working capital, and use operating cash flow to reduce debt and finance costs. He explicitly frames strategy as concentrating on areas of deep technical expertise rather than aggressive diversification, and expects improved operating leverage, stronger cash generation and gradual deleveraging as Dahej reaches full contribution and the US project progresses.

Strategic initiatives (last 24 months)

InitiativeDescriptionStatus / targetsSource
West Virginia MAN & food-ingredients complex40,500 TPA MAN from local butane; 30,000+ TPA malic/fumaric acid; proprietary low-capex technology; modular build by TCL-TE; positioned to replace imports in an under-served US market and export to LATAM/EuropeFirst MAN unit started Jan 2026; full commissioning slipped to Dec 2026; cost revised from USD 255 m to USD 340 m (incl. working capital and cash buffer); food-ingredient ramp requires customer approvalsICRA Aug 2026; company filings
Dahej Phase II stabilisation~96,000 TPA PAN and ~10,000 TPA fumaric acid commissioned FY2025Fully stabilised; ~95% utilisation in Q1 FY27FY26 AR; Q1 FY27 presentation
Balance-sheet repair programmePreferential issues (~INR 507 Cr in FY26); board approval for up to INR 750 Cr via debt/equity incl. possible QIP; reported plan for INR 200–250 Cr preferential issue; refinancing; US senior secured term loan up to USD 130 m (reports cite USD 130–180 m facility)Ongoing; Fund Raising Committee met 30 Aug 2026Filings; news
Non-core asset monetisationSale of four windmills (INR 10.35 Cr) to TN Oxygen; OOSB divestment via Cheminvest (reported INR 100–150 Cr); possible sale of Ultramarine & Pigments stakeWindmills approved; others pending/unconfirmedFilings; CNBC-TV18 via secondary
Trade protectionSuccessful sunset review: anti-dumping duty on PAN from China and Korea continued for five years from Aug 2026EffectiveCustoms Notification 20/2026
Operational excellenceRe-catalysation of Ranipet PAN; procurement transformation (Best Procurement Transformation Award 2025); inventory reduction; real-time quality monitoringOngoingFY26 AR; Q1 FY27 presentation
ESG 2030 targets-25% GHG, -10% water consumption, -10% industrial waste vs. FY2022-23 baseline; zero accidents; 100% digitally enabled workforceFY26 progress reported (see Section 20)FY26 AR
Leadership build-outCEO role (Sanjay Sinha); President-Finance (Feb 2026); US subsidiary CEO (Dec 2025); auditor rotation to PKF Sridhar & SanthanamCompletedFilings

Medium-term guidance

TCL does not publish quantitative revenue/margin guidance. The only forward-looking quantitative commitments identified are the US project budget (USD 340 m) and timeline (full commissioning Dec 2026), the 2030 ESG targets, and the fund-raising envelope (up to INR 750 Cr). Management's AGM-notice language anticipates improved productivity and profitability as projects reach optimal utilisation, without numbers.

Products & Services

PAN chain (bulk commodity, ~84% of revenue)

ProductDescription & specificationsManufacturing site / capacityTarget customers / applicationsStatus / yearPricing
Phthalic Anhydride (PAN/PA)Produced by catalytic oxidation of ortho-xylene; flake/molten forms. Company claims top-3 global producer statusRanipet (TN) and Dahej (GJ). Total PAN capacity ~1,72,000 TPA incl. Dahej phase I per ICRA, with Dahej phase II adding ~96,000 TPA in FY2025 (ICRA text is ambiguous whether 172k includes phase II)Plasticisers (PVC), unsaturated polyester resins, alkyd resins/paints, CPC pigments, dyes, herbicides, fire retardants, polyester polyols, rubber scorch inhibitorsFlagship since 1973/76; Dahej phase II FY2025; Dahej at ~95% utilisation in Q1 FY27Spot/contract; tracks PAN–OX spread; protected by Indian anti-dumping duty (USD 40.08/MT China, USD 140.17/MT Korea, from Aug 2026)
Diethyl Phthalate (DEP)Phthalate ester from ethanol + PAN; high solvency/purityRanipetFragrance and cosmetics solvent; plasticiser for medical/packaging plastics; adhesives, insect repellentsEstablished—
Phthalate esters (other)PAN downstream derivativesRanipet/Dahej (not specified)PlasticisersEstablished; contribution growing (ICRA)—
Phthalimide (PID)PAN derivativeNot specifiedAgro/pharma intermediatesListed in ICRA company profile—

MAN and food-acids chain (specialty, ~16% of revenue)

ProductDescription & specificationsManufacturing site / capacityTarget customers / applicationsStatus / yearPricing
Maleic Anhydride (MAN)Butane-based oxidation routeOOSB Kemaman, Malaysia: 50,000 TPA (largely idle FY26, positive EBITDA Q1 FY27). TCL Specialties, West Virginia: ~40,500 TPA (first phase start-up Jan 2026; full commissioning targeted Dec 2026)UPR/composites, lubricant additives, agrochemicals, feedstock for malic/fumaric acid; US North-East and Mid-West customers (under-served regionally)Malaysia: long-established; US: 2026Not disclosed; MAN realisations pressured by Chinese supply (ICRA)
Malic AcidAcidulant; food-grade and pharma-grade (company cites itself as among few Indian producers of both)Ranipet; US food-ingredients plant (30,000+ TPA combined malic + fumaric)Beverages, confectionery, food processing, oral care/skincare, metal cleaning, textile dyeing, paint anti-skinningIndia: since 1992; US: ramp-up from Dec 2026 (customer approvals required)—
Fumaric AcidAcidulant, leavening agent; API gradeRanipet; Dahej phase II (~10,000 TPA); US plantBakery, tortillas, animal feed, bath salts, UPR and alkyd resins, inks, pharmaceutical APICompany claims largest Indian producer—
Food ingredients (historic)Tartaric acid and salts, maleic acid cited in older company descriptionsNot specifiedFoodCurrent production not confirmed in FY26 AR—

Services and other

OfferingDescriptionStatus
TCL Technology & Engineering (TCL-TE)Design, supply and construction of modular, IoT-enabled process plants and skids; built US plant modules in India (plus fabrication in Japan and the US)Captive; external revenue not disclosed
Proprietary process technology"Hi-efficiency, low investment" MAN/food-acid technology licensed intra-group to TCL USA; described by the company as patentedCaptive
Wind power (Tamil Nadu)Four windmillsBoard approved sale to TN Oxygen Pvt Ltd for INR 10.35 Cr (Aug 2026)

Financial Narrative

Income statement

Sources and notes: Revenue, gross profit, EBIT, finance costs — S&P Global Market Intelligence (StockAnalysis, data updated Aug 2026). EBITDA, PBT, PAT — FY26 Annual Report five-year performance snapshot and FY26 results filing (PBT FY26 per filing INR -201.8 Cr; AR snapshot INR -194 Cr). EPS derived as PAT ÷ weighted shares (FY22–FY25: 102.39 m shares; FY26 weighted ≈112.6 m after Aug and Dec 2025 allotments); no dilutive instruments identified, so diluted = basic. DPS derived from cash dividends paid in the following year (INR 25.6 Cr, 15.4 Cr, 10.2 Cr) and Screener payout ratios; no dividend for FY25 or FY26. ICRA computes FY26 OPBDIT/OI at -1.4% (≈INR -24 Cr) versus company EBITDA of INR -16 Cr — definitional difference.

Margins and growth

Revenue CAGR: FY2022–FY2026 (4-year) -3.5%; FY2021–FY2026 (5-year, FY21 base ≈INR 1,086 Cr derived from S&P growth rate) ≈+9.8%, consistent with Screener's ~10% five-year standalone sales CAGR.

Commentary. FY2022 was a super-cycle year: post-COVID restocking, tight Asian PAN supply and a strong MAN market lifted revenue 84% and EBITDA margin to ~23%. From FY2023 the PAN–OX spread compressed as Chinese and Korean capacity returned and new large Indian capacities came on stream (ICRA), cutting gross margin by almost half by FY2024. FY2024–FY2025 revenue was broadly flat because Dahej volumes offset lower realisations, but EBITDA stayed near INR 70 Cr. FY2026 is the inflection low: revenue fell 15% on weaker volumes and pricing (Middle East conflict, tariff disruption, subdued global demand per the Chairman's letter), operating efficiencies fell with lower utilisation, finance costs nearly doubled to INR 80.6 Cr as capex debt matured into the P&L, and OOSB's MAN plant was largely idle. The negative tax line (S&P: INR -24.9 Cr TTM credit) cushioned PAT only marginally.

Quarterly trajectory (consolidated)

Sources: Quarterly results filings via Kotak Securities, MarketsMojo, Univest; Q4 FY26 PAT derived as FY26 PAT minus 9M (aggregator reports of INR -10.83 Cr / -27.42 Cr appear to be standalone figures). Q1 FY27: EBITDA INR 35.9 Cr (6.6% margin) vs. INR -24.5 Cr in Q1 FY26; interest expense INR 51.97 Cr (9.5% of revenue); standalone PAT turned positive at INR 14.21 Cr vs. INR -13.83 Cr a year earlier. Q1 FY27 revenue was the highest quarterly print in over two years, driven by improved PAN–OX spreads, Dahej at ~95% utilisation and positive OOSB EBITDA, though working-capital constraints limited raw-material procurement (ICRA, company presentation).

Balance sheet

Sources: S&P Global Market Intelligence (StockAnalysis, updated 4 Aug 2026); company net debt per FY26 Annual Report snapshot. The company's net-debt measure is ~INR 276 Cr lower than S&P's in FY26, most likely because the company nets long-term investments (e.g., its 14.38% stake in Ultramarine & Pigments, INR ~154 Cr in long-term investments) and excludes leases.

Commentary. The balance sheet has been transformed in four years: total debt rose 13x from INR 165 Cr to INR 2,175 Cr while CWIP rose from INR 64 Cr to INR 2,518 Cr — i.e., more than half of gross PP&E is non-earning US construction. Equity was rebuilt in FY26 only through ~INR 507 Cr of preferential equity (Aug and Dec 2025); without it, book equity would have fallen below INR 1,100 Cr. Working capital swung to INR -500 Cr as short-term debt and "other current liabilities" (INR 440 Cr, likely capex creditors and current maturities) ballooned; at 30 Jun 2026 consolidated current liabilities exceeded current assets by INR 742 Cr. Unencumbered consolidated cash was only ~INR 64 Cr at 31 Mar 2026 (ICRA).

Cash flow

Source: S&P Global Market Intelligence (StockAnalysis). FY2026 full-year cash-flow statement figures were not available in the sources reviewed; the trailing-twelve-month period to 30 Jun 2026 shows operating cash flow of INR -131 Cr, capex of INR 599 Cr, free cash flow of INR -730 Cr, D&A of INR 91 Cr and net borrowing of INR 284 Cr (S&P, Oct 2026). FY2026 equity inflow from preferential issues: ~INR 506.8 Cr. Note that cash interest paid (INR 128 Cr in FY25) far exceeds P&L finance cost (INR 44.5 Cr) because most interest on US project debt is capitalised during construction — a significant P&L flattering effect that will reverse once the plant is commissioned.

Commentary. Cumulative free cash flow over FY2023–FY2025 was INR -1,561 Cr, funded by ~INR 1,478 Cr of net new debt and cash drawdown; FY2026 added a further ~INR 700 Cr+ of negative FCF funded by equity and debt. Operating cash flow has been volatile and is now negative, reflecting stretched receivables (standalone debtor days 88 in FY26 vs. 40 in FY25) and losses.

Key ratios

Sources: ROE/ROCE — FY26 Annual Report snapshot; ROIC FY22–FY25 — S&P Global; FY26 ROIC derived (NOPAT on EBIT of INR -107 Cr at 25% tax over invested capital ≈INR 3,670 Cr); current ratio, D/E, asset turnover — S&P (FY26 derived from balance sheet); CCC and debtor days — Screener (standalone). Net debt/EBITDA FY26 is not meaningful because EBITDA is negative. ICRA metrics (consolidated): Total debt/OPBDIT 32.1x FY25 and -91.3x FY26; interest coverage 1.1x FY25, -0.3x FY26, 0.6x Q1 FY27; TOL/TNW 2.3x FY25, 2.0x FY26.

Commentary. Every return and coverage metric has collapsed from best-in-class (FY22 ROCE 28%) to value-destructive. The swing in the standalone cash conversion cycle from -21 to +61 days in a single year is particularly notable — TCL historically operated with negative working capital (supplier credit from Reliance on OX exceeded receivables and inventory), and the loss of that structural float (days payable fell from 103 to 63) suggests suppliers have tightened terms as credit quality weakened. Lenders' financial covenants were breached in FY26 and waived (ICRA).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Organic chemicals segment revenue (INR Cr, consolidated)

2,083.12,049.51,735.5

Segment pre-tax result (INR Cr, consolidated PBT)

-35-41-202

Segment pre-tax margin (%)

-1.7-2.0-11.6

YoY revenue growth (%)

-2.3-1.6-15.3

Contribution to total revenue (%)

100100100

Group Entities

EntityCountryTCL ownershipRole

Thirumalai Chemicals Ltd

India

Parent

Ranipet PAN, malic/fumaric acid, DEP; TCL-TE engineering division

TCL Intermediates Pvt Ltd (TCLIPL)

India

100%

Dahej PAN (phase I & II) and fumaric acid; designated material subsidiary

Cheminvest Pte Ltd

Singapore

100%

Holding company; majority shareholder of OOSB

Optimistic Organic Sdn Bhd (OOSB)

Malaysia

100% (step-down)

50,000 TPA butane-based MAN plant at Kemaman; largely non-operational in FY26; divestment being explored

TCL Global B.V.

Netherlands

100%

Holding/trading (US structure)

TCL Inc

USA

100%

US holding entity

TCL Specialties LLC

USA

100% (step-down)

West Virginia MAN (40,500 TPA) and food-ingredients (30,000+ TPA) complex

Lapiz Europe Ltd

UK

100%

European trading/marketing

Results by Segment

MetricFY2022FY2023FY2024FY2025FY2026

Standalone revenue from operations (INR Cr)

1,4381,8471,9872,1521,360

Consolidated revenue from operations (INR Cr)

1,998.22,132.22,083.12,049.51,735.5

Standalone PAT (INR Cr)

1521203682-65

Consolidated PAT (INR Cr)

281.289.8-38.8-46.1-167.9

Implied subsidiaries + eliminations PAT (INR Cr, derived)

129.2-30.2-74.8-128.1-102.9

Standalone EBITDA (INR Cr, company)

25522012618320

Consolidated EBITDA (INR Cr, company)

4522167069-16

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

1,998.22,132.22,083.12,049.51,735.5

Total income incl. other income (INR Cr)

2,009.82,162.42,102.52,070.11,754.2

Gross profit (INR Cr)

772.3559.6380.7419.2333.7

Operating income / EBIT (INR Cr)

387.7131.3-5.8-8.6-107.0

EBITDA (INR Cr, company-reported)

4522167069-16

Finance costs (INR Cr)

16.926.235.944.580.6

Profit before tax (INR Cr)

375129-35-41-202

Net income (INR Cr)

281.289.8-38.8-46.1-167.9

EPS basic and diluted (INR, derived)

27.468.77-3.79-4.50-14.92

Dividend per share declared (INR)

2.51.51.000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

38.6526.2518.2820.4519.23

Operating (EBIT) margin (%)

19.46.2-0.3-0.4-6.2

EBITDA margin (%)

22.610.13.43.4-0.9

Net margin (%)

14.074.21-1.86-2.25-9.68

Revenue growth YoY (%)

84.046.71-2.30-1.61-15.32

Income Statement

MetricQ1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027

Revenue from operations (INR Cr)

450.05445.37415.85424.25546.67

Net profit (INR Cr)

-59.96-33.38-46.57-28.00-43.67

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

1,861.62,360.23,320.33,806.84,736.6

Cash and short-term investments (INR Cr)

553.0457.2445.9182.967.9

Short-term debt incl. current maturities (INR Cr)

25.6293.6350.8305.9527.2

Long-term debt (INR Cr)

135.4147.6812.51,400.71,565.8

Lease liabilities (INR Cr)

4.172.988.479.181.7

Total debt incl. leases (INR Cr)

165.1514.01,251.71,785.62,174.7

Net debt, S&P basis (INR Cr)

-387.956.8805.81,602.72,106.9

Net debt, company-reported (INR Cr)

-440-315301,3491,831

Shareholders' equity (INR Cr)

1,085.01,191.91,146.21,155.71,563.6

Goodwill and intangibles (INR Cr)

0.060.190.170.140.33

Net working capital (INR Cr)

475.8187.0105.035.0-500.5

Net PP&E incl. CWIP (INR Cr)

659.51,077.31,911.12,603.53,768.8

Capital work-in-progress (INR Cr)

63.6406.41,199.61,352.12,518.4

Inventory (INR Cr)

242.0319.2250.8247.3184.7

Receivables (INR Cr)

158.8117.6197.2211.4217.3

Book value per share (INR)

105.97116.41111.95112.87129.66

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (INR Cr)

220.8402.354.1237.1-65.9

Capital expenditure (INR Cr, outflow)

61.073.6362.8810.7612.9

Free cash flow (INR Cr)

159.8328.7-308.6-573.7-678.8

Dividends paid (INR Cr)

022.325.615.410.2

Share buybacks (INR Cr)

00000

Net debt issued / (repaid) (INR Cr)

-15.9-29.0267.6697.4512.7

Cash interest paid (INR Cr)

22.318.619.679.1127.8

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE (%, company-reported)

268-3-4-11

ROCE (%, company-reported)

28190.40.5-10

ROA (%, PAT / year-end assets, derived)

15.13.8-1.2-1.2-3.5

ROIC (%)

21.675.55-0.18-0.29-2.2

Current ratio (x)

1.861.221.101.040.61

Debt / equity (x)

0.150.431.091.551.39

Net debt / EBITDA (x, company basis)

-0.97-0.147.5719.55-114.4

Interest coverage, EBIT / finance cost (x)

22.95.0-0.16-0.19-1.33

Asset turnover (x)

1.251.010.730.570.41

Cash conversion cycle, standalone (days)

-44-28-32-2161

Debtor days, standalone

2418304088

Revenue by Region and Revenue by Region (%)

MetricFY2026

Revenue from India (INR Cr)

1,266

Export share of total revenue (%)

10

Exports to Europe (% of exports)

43

Exports to North America (% of exports)

25

Exports to Asia (% of exports)

19

Exports to Africa (% of exports)

13

Share Price & Returns

HorizonReturnSource / date

1 year

-49.6%

S&P Global, 7 Oct 2026

3 years

~-27% (cumulative)

Anand Rathi, Aug 2026

5 years

~+5% CAGR

Screener, mid-2026

10 years

~+20% CAGR

Screener, mid-2026

52-week range

INR 143.5 – 328.8

Fyers/Anand Rathi, Aug–Sep 2026

Beta (5Y)

0.37

S&P Global

Relative performance

Underperformed commodity chemicals sector by ~49 pp over 1 year (as of Aug 2026)

MarketsMojo

Share Price and Market Valuation

MetricFY2021FY2022FY2023FY2024FY2025

Share price at FY end (INR)

82.55260.41169.94233.33242.85

Market capitalisation (INR Cr)

875.42,723.51,759.52,396.92,486.5

Enterprise value (INR Cr)

816.52,394.61,231.82,762.43,452.3

EV/Sales (x)

0.751.200.581.331.68

EV/EBITDA (x)

3.705.436.7554.4570.75

P/B (x)

1.092.511.482.092.15

Dividend yield (%)

2.670.960.880.430

Capital Markets

MetricThirumalai ChemicalsI G Petrochemicals

Price

INR 147.70 (7 Oct 2026)

~INR 555 (18 Sep 2026)

Market cap

~INR 1,781 Cr

~INR 1,709 Cr

Enterprise value

~INR 3,888 Cr

—

P/E (TTM)

n/m (loss)

Not meaningful/very high (near-zero TTM profit)

EV/Sales (TTM)

2.12x—

EV/EBITDA (TTM)

83.8x—

P/B

1.14x0.78x

P/S

0.97x

~0.87x (derived from FY26 revenue)

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

2.51.51.000

Standalone payout ratio (%)

17132800

Analyst Ratings & Targets

DateLong-term ratingShort-term ratingDriver

4 Aug 2023

A+ (Stable)

A1+

Peak

14 Feb 2024

A+ (Negative)

A1+

Weak FY24 margins, capex

24 May 2024

A+ (Negative)

A1

—

3 Dec 2024

A+ (Negative)

A1

Enhanced limits

27 May 2025

A (Negative)

A2+

FY25 performance; US capex

26 Aug 2025

A- (Negative)

A2+

Q1 FY26 weakness

25 Nov 2025

A- (Negative)

A2+

Reaffirmed; NCDs rated

12 Jan 2026

BBB+ (Negative)

A2

Weak PAN–OX spreads

9 Jun 2026

BBB+ (Negative)

A2

Material-event update

13 Aug 2026

BBB (Negative)

A3+

US cost to USD 340 m; delay; covenant breaches

Capital Instruments

InstrumentAmount (INR Cr)Drawn / issuedMaturityCoupon

Term Loan I

200

18 Dec 2023

3 Sep 2031

—

Term Loan II

200

24 Oct 2024

30 Nov 2031

—

Term Loan III

25

1 Nov 2024

31 Dec 2031

—

Term Loan IV

20

15 Apr 2026

15 Apr 2029

—

NCD tranche 1

33

9 Jun 2025

4 Jun 2027

11.25%

NCD tranche 2

33

9 Jun 2025

4 Jun 2028

11.75%

NCD tranche 3

34

9 Jun 2025

4 Jun 2029

12.25%

Working-capital limits (fund-based)

334.5—

Revolving

—

US subsidiary project debt

Not separately disclosed (guaranteed by TCL); new senior secured term loan up to USD 130 m in process

———

“—” = not publicly disclosed.

Analyst Conclusions

Management guidance

No numeric guidance. Qualitative: improve EBITDA via volumes and realisations; control working capital; deleverage from operating cash flow; complete US commissioning by December 2026; raise up to INR 750 Cr and monetise non-core assets. Consensus growth expectations: not available (no sell-side coverage).

Bull case

  1. Operating trough is behind: Q1 FY27 delivered INR 35.9 Cr EBITDA (6.6%) versus a loss a year earlier, the highest revenue in two years, Dahej at ~95% utilisation and positive OOSB EBITDA — with the anti-dumping duty secured to 2031, normalised Indian PAN spreads could restore INR 150–250 Cr of annual group EBITDA from existing Indian assets (FY23–FY24 levels were INR 70–216 Cr; FY22 INR 452 Cr).

  2. US asset is close to cash generation: with MAN already producing in phases and full commissioning targeted for December 2026, roughly INR 2,500 Cr of CWIP converts to earning assets; ICRA expects higher-margin MAN and food acids to lift group margins and diversify geography.

  3. Asset monetisation and equity support reduce tail risk: demonstrated access to ~INR 507 Cr equity in FY26 (including promoters), an INR 750 Cr enabling resolution, OOSB and windmill sales; at P/B of 1.14x the equity is priced near distressed levels.

Bear case

  1. Serial cost and time overruns: budget has risen from USD 150 m (2022) to USD 340 m (2026) and timelines have slipped repeatedly; the funding gap is to be met with more debt, while capitalised interest will hit the P&L once the plant is commissioned — FY27–FY28 earnings may remain negative even with operating improvement.

  2. Liquidity is the binding constraint: INR 64 Cr of unencumbered cash, INR 742 Cr negative working capital, covenant breaches, rising repayments (INR 388 Cr over FY27–FY28), short-term rating at A3+ and suppliers tightening credit (days payable 103 → 63) create refinancing and execution risk; working-capital shortages already capped Q1 FY27 volumes.

  3. Dilution and structural competitiveness: any further INR 200–750 Cr of equity at ~INR 150/share could add 11–42% to the share count; core PAN remains a commodity where IGPL has larger scale and integration, and Chinese oversupply in MAN/food acids may limit US pricing.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
Q2 FY27 results~3 Nov 2026 (estimated)Sustainability of PAN–OX spread recovery; interest burden
Closing of US senior secured term loan (USD 130–180 m)H2 2026Funds completion; removes cost-overrun funding gap
Execution of INR 200–750 Cr capital raise (preferential/QIP)H2 FY27Liquidity; dilution
Full commissioning of West Virginia complexDec 2026Single largest value driver
Food-ingredient customer qualifications in US2,027Revenue ramp timing
OOSB divestmentFY27Removes loss-maker; cash inflow
ICRA rating action / outlookPost-resultsFunding cost and covenants
NCD tranche 1 maturity (INR 33 Cr)4 Jun 2027First market-debt test
GST SCN outcomesFY27Contingent cash outflow
PAN–OX spread and OX pricingContinuousCore earnings driver

Analyst verdict

Thirumalai Chemicals is a fundamentally sound commodity franchise trapped in a poorly timed, over-budget, debt-funded growth project. The Indian PAN business retains real advantages — a duopoly market position, assured Reliance feedstock, best-in-class energy integration and, as of August 2026, five more years of anti-dumping protection — and Q1 FY27 showed that, with even moderately better spreads, the standalone business returns to profit (INR 14 Cr PAT). The problem is the group balance sheet. In four years TCL has moved from INR 440 Cr of net cash to INR 1,831 Cr of company-reported net debt, its credit rating has fallen five notches to BBB (Negative)/A3+, covenants have been breached, and the West Virginia budget has more than doubled from its original plan to USD 340 million, with full commissioning now December 2026.

The investment case therefore hinges on a narrow sequence: close the US term loan, raise domestic capital, sell OOSB, commission West Virginia on the revised schedule, and qualify US food-ingredient customers quickly enough to generate cash before repayments intensify in FY2028. Each step is plausible — management has delivered INR 507 Cr of equity and phased US start-up — but the track record of slippage argues for skepticism, and the equity will likely absorb further dilution along the way.

At ~1.1x book and ~0.97x sales, the market already discounts significant distress, which creates asymmetric upside if the US plant ramps cleanly and Indian spreads hold. However, until liquidity is demonstrably repaired and the US asset is producing at scale, we view TCL as a high-risk, special-situation equity rather than a quality cyclical. Stance: speculative / avoid for risk-averse capital; monitor the Q2–Q3 FY27 prints, the US financing close and December 2026 commissioning as the triggers for re-rating. Credit investors should note that NCD coupons above 11% already price meaningful default-risk premia.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundEducationAge

R. Parthasarathy (DIN 00092172)

Chairman & Managing Director

Long-serving CMD (re-appointed multiple terms); President of Indian Chemical Council 2007–2011 (VP and President); has run manufacturing, technology development, marketing and start-ups in India, Europe and the US; Lifetime Achievement Award (FY26)

—

~74 (GlobalData)

Ramya Bharathram (DIN 06367352)

Managing Director & CFO; heads Strategy and Specialty Chemicals

On board since 3 Nov 2014; ~16+ years at TCL; previously at a trade-policy/indirect-tax law firm and Deloitte & Touche; re-appointed director (retires by rotation) at Aug 2026 AGM

Commerce graduate; Inter CA

54 (DOB 24 Jul 1972)

Sanjay Sinha

Chief Executive Officer

Listed as CEO in FY26 Annual Report and S&P profile; member of Risk Management Committee. Reported prior role as Executive Director, Emerging Business at Archean Group (GlobalData — not confirmed in company filings)

——

Anand Kumar

President – Finance (Senior Management Personnel)

Appointed 14 Feb 2026

——

Aditya Sharma

Company Secretary & Compliance Officer

Signatory on 2026 filings

——

Vinod Tiwari

CEO, TCL Specialties LLC (US subsidiary)

Joined Dec 2025

——

P. Mohana Chandran Nair

Non-Executive Director; MD of TCL Intermediates Pvt Ltd

~11 years at TCL (formerly President-Manufacturing / Whole-time Director); 36+ years at Rashtriya Chemicals & Fertilizers, rising to Executive Director/Head of Operations

Chemical Engineer

73

“—” = not publicly disclosed.

Board of Directors

DirectorCategoryCommittee rolesPrior / other rolesAge

R. Parthasarathy

Executive Chairman & MD (Promoter)

CSR, Project Review

See above

~74

Ramya Bharathram

Executive MD & CFO (Promoter group)

Risk Management, Fund Raising

Director, Jasmine Ltd; N.R. Swamy Investments; Indian Chemical Council

54

P. Mohana Chandran Nair

Non-Executive

Stakeholders Relationship

Ex-RCF

73

Rajeev M. Pandia

Independent

Chair: Nomination & Remuneration, Business Review, Risk Management; Audit; Fund Raising; Project Review

IIT Bombay / Stanford; former VC & MD Herdillia Chemicals (SI Group India); ex-President ICC; boards of Transpek Industry, Supreme Petrochem

76

M. Somasundaram

Independent

Chair: Audit; Fund Raising; Project Review; Business Review

Ex-CFO of CAMS (led IPO); SRF, Hindustan Unilever; B.Com, ICWA, ACS

63

Raj Kataria

Non-Executive (described as Independent in Annual Report bio; "Non-Executive" in AGM notice)

Chair: Stakeholders Relationship; Audit; NRC

Co-founder, Arpwood Capital; ex-MD DSP Merrill Lynch; director EIH Ltd

70

Bhama Krishnamurthy

Independent

Chair: CSR; Audit; NRC; Risk Management

Ex-Country Head & CGM, SIDBI; boards incl. Cholamandalam Investment, Just Dial, Muthoot Microfin; TCL Global BV

71

D. Sabitha

Independent

Audit; Stakeholders; CSR

Retired IAS (1988 batch), ex-Additional Chief Secretary, Tamil Nadu; director TCLIPL

66

Meghav Mehta

Independent

CSR; Business Review; Risk Management

CEO Deepak Chem Tech; director Deepak Nitrite, Deepak Phenolics

39

Arun Alagappan

Independent (resigned w.e.f. 31 Mar 2026)

—

Executive Vice Chairman, Coromandel International (Murugappa Group)

49

Arun Ramanathan

Independent (retired 21 Jul 2025)

—

Ex-Union Finance Secretary

77

R. Sampath

Non-Executive (resigned 14 Aug 2025; relative of CMD)

——80

Directors' Remuneration

NamePeriodRemunerationSource

R. Parthasarathy (CMD)

H2 FY2023 related-party disclosure

INR 405.60 lakh

NSE RPT filing (May 2023)

Ramya Bharathram (MD)

H2 FY2023 related-party disclosure

INR 245.76 lakh

NSE RPT filing (May 2023)

FY2026 KMP remuneration

FY2026

——

Shareholding Trend

Holder categoryJun 2025 (%)Aug 2025 (%)Dec 2025 (%)Mar 2026 (%)Jun 2026 (%)

Promoter & promoter group

41.8736.1337.1337.1337.13

Mutual funds

0.737.918.468.91—

Foreign institutional investors

1.882.091.972.06—

Other domestic institutions

0.321.221.011.02—

Retail and others

55.1952.6551.4250.8651.33

Competitive Landscape

Key Competitors

CompetitorCountryProduct overlapRelative positioning

I G Petrochemicals Ltd (IGPL)

India

PAN, MAN, DEP, benzoic acid, plasticisers

India's largest PAN producer (~50% domestic share), sole domestic MAN producer; five PAN plants and four MAN plants at Taloja; adding 1,00,000 TPA plasticiser forward integration

Chinese PAN producers (various)

China

PAN

Price setters for Asian PAN; subject to Indian ADD (USD 40.08/MT)

Aekyung Chemical and other Korean PAN producers

South Korea

PAN

Subject to Indian ADD (USD 140.17/MT)

Thai PAN producers

Thailand

PAN

DGTR found negative injury margin; no duty — potential import channel

UPC Technology / Nan Ya Plastics

Taiwan

PAN, plasticisers

—

Polynt Group

Italy/global

PAN, MAN, UPR

Integrated European/US anhydrides player

Huntsman Corp

USA

MAN (US)

Leading US MAN producer — direct competitor to TCL Specialties

Chinese MAN producers (various)

China

MAN

Oversupply source depressing Asian MAN prices; drove OOSB idling

Bartek Ingredients

Canada

Malic acid, fumaric acid

Leading North American food-acids producer — direct competitor to US food-ingredients plant

Fuso Chemical

Japan

Malic acid

Asian food-acids competitor

Changmao Biochemical / Chinese malic acid producers

China

Malic and fumaric acid

Low-cost Asian food-acid supply

Stepan / Koppers (historic PAN in US)

USA

PAN

US PAN producers (relevance to TCL limited given TCL's US focus is MAN)

Peer Comparison FY2026

MetricThirumalai Chemicals (FY2026, consolidated)I G Petrochemicals (FY2026)

Revenue

INR 1,735.5 Cr (revenue from ops)

INR 1,953.7 Cr (total revenue)

Revenue growth YoY

-15.3%-12.5%

EBITDA margin

-0.9%—

Net profit

INR -167.9 Cr

~INR 2.2 Cr (four quarters to Mar 2026, standalone)

R&D intensity

0.11%—

Market cap (Sep–Oct 2026)

~INR 1,781 Cr

~INR 1,709 Cr

P/B

1.14x0.78x

Exports % of revenue

~10%

~11%

Recent Developments

--

Company Snapshot

$200.4M

Revenue

477

Employees

1944

Founded

Mumbai, India

Headquarters

SWOT Analysis

Strengths

  • Established No. 2 position in Indian PAN with five decades of operating history and relationships across plasticiser, CPC, paint and UPR customers (ICRA, Aug 2026).
  • Assured OX feedstock from Reliance Industries under an assured-offtake model (ICRA).
  • Structural energy advantage: over 90% of PAN energy from recovered heat; 1,05,115 GJ of waste-heat energy generated on-site in FY26 (FY26 AR).
  • Proven ability to turn on profitability when spreads normalise: FY22 EBITDA of INR 452 Cr (22.6% margin) and ROCE of 28% (FY26 AR snapshot); Q1 FY27 standalone PAT of INR 14.2 Cr even amid stress.
  • Regulated-market credentials: FSSC 22000, HACCP, Kosher, Halal, FAMI-QS and Responsible Care certifications enable food/pharma sales (FY26 AR).
  • Demonstrated access to equity capital: ~INR 507 Cr raised via preferential issues in FY26, including INR 56 Cr from the promoter group (exchange filings).
  • Safety record: zero LTIFR and zero fatalities in FY26; zero liquid discharge at Ranipet (FY26 AR; ICRA).

Weaknesses

  • Three consecutive loss years: consolidated PAT of INR -38.8 Cr (FY24), -46.1 Cr (FY25), -167.9 Cr (FY26).
  • Leverage: total debt INR 2,175 Cr vs. equity INR 1,564 Cr (D/E 1.39x); FY26 EBITDA negative; ICRA interest coverage -0.3x (FY26).
  • Liquidity stress: unencumbered cash ~INR 64 Cr (Mar 2026); current liabilities exceed current assets by INR 742 Cr (Jun 2026); FY26 covenant breaches waived (ICRA).
  • Working-capital deterioration: standalone debtor days 88 (FY26) vs. 40 (FY25); CCC swung from -21 to +61 days (Screener).
  • Negligible R&D: INR 1.95 Cr (0.11% of revenue), zero patents granted in FY26 (FY26 AR).
  • Idle Malaysian asset: OOSB's 50,000 TPA MAN plant largely non-operational in FY26 (ICRA), with impairment on non-operational plants.
  • Governance concentration: combined Chair-MD; prior committee-composition non-compliance penalties (FY26 secretarial compliance report); three board departures in FY26.

Opportunities

  • US MAN and food acids: 40,500 TPA MAN and 30,000+ TPA food-acid capacity in an under-served US market; ICRA expects higher operating margins once stabilised.
  • Anti-dumping protection through 2031: duty of USD 40.08/MT (China) and USD 140.17/MT (Korea) supports Indian spreads (Customs Notification 20/2026).
  • Spread recovery: Q1 FY27 EBITDA margin of 6.6% vs. -5.5% a year earlier; ICRA notes improved PAN–OX spreads.
  • Portfolio pruning: OOSB sale (reported INR 100–150 Cr) would remove a loss-maker and release cash; windmill sale INR 10.35 Cr.
  • Indian infrastructure demand: DGTR found domestic PAN demand growing even with duties in force.
  • Capitalised-interest unwind and operating leverage: with ~INR 2,500 Cr of CWIP moving into operation, revenue-generating assets nearly double.

Threats

  • Further US cost/timeline slippage: cost already rose from USD 255 m to USD 340 m and full commissioning slipped from mid-2026 to Dec 2026 (ICRA).
  • Refinancing and repayment wall: principal repayments of ~INR 170 Cr in FY27 and ~INR 218 Cr in FY28 (ICRA) with NCD maturities from Jun 2027.
  • Rating spiral: five ICRA downgrades from A+ to BBB (Negative) in ~15 months; short-term rating now A3+, raising funding costs.
  • Chinese oversupply in MAN and food acids pressuring realisations (ICRA; FY26 AR).
  • Equity dilution: shares outstanding +14.3% YoY; a further INR 200–750 Cr raise at ~INR 150/share would imply material additional dilution.
  • Tax/regulatory claims: GST SCNs at Ranipet (INR 22.93 Cr) and Vadodara; contingent liabilities of ~INR 1,234 Cr (Screener, standalone, likely including subsidiary guarantees).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 May 2025Q4 FY25 results announcedConfirmed FY25 consolidated loss of INR 46.1 Cr
27 May 2025ICRA downgrades to [ICRA]A (Negative)/A2+First of five downgrades; cites FY25 performance and US capex
9 Jun 2025INR 100 Cr NCDs issued (11.25%/11.75%/12.25%, maturing 2027–2029)High-cost funding signals tighter credit
15 Aug 2025Q1 FY26: revenue INR 450 Cr, PAT INR -59.96 CrWorst quarterly loss of the cycle
26 Aug 20251.63 Cr shares allotted at INR 277 to non-promoters (~INR 450.6 Cr); ICRA downgrade to A- (Negative)Major equity infusion; promoter stake diluted from 41.9% to 36.1%
22–29 Oct 2025Board meetings on fund-raising; promoter preferential issue of INR 56.14 Cr approvedPromoter commitment signal
Nov 2025Q2 FY26: revenue INR 445 Cr, PAT INR -33.38 CrContinued losses
25 Nov 2025ICRA reaffirms A- (Negative); assigns NCD ratingTemporary stabilisation
28 Nov 2025Postal ballot approves promoter preferential issue—
12 Dec 2025TCL Specialties LLC begins pre-commissioning in West Virginia; Vinod Tiwari appointed US CEOProject milestone
23 Dec 202518.97 lakh shares allotted to promoter group at INR 296Promoter stake to 37.13%
2–3 Jan 2026US start-up activities and first-phase MAN productionFirst US output
12 Jan 2026ICRA downgrade to [ICRA]BBB+ (Negative)/A2Exit from "A" category; weak PAN–OX spreads
14 Feb 2026Q3 FY26: revenue INR 415.9 Cr, PAT INR -46.57 Cr; Anand Kumar appointed President-Finance; Arun Alagappan resignationLeadership and governance changes
30 May 2026FY26 results: consolidated revenue INR 1,735.5 Cr, PAT INR -167.9 Cr; INR 4.44 Cr impairment; auditor change proposed; US term loan up to USD 130 m in advanced stageTrough year confirmed
30 May 2026FY26 secretarial compliance report references prior committee non-compliance penalties and appealsGovernance flag
9 Jun 2026ICRA material-event update; ratings maintained at BBB+ (Negative)—
1 Jul 2026Trading window closed for Q1 resultsRoutine
11–12 Jul 2026FY26 Annual Report and BRSR filedDisclosure
30 Jul 2026GST show-cause notice of INR 22.93 Cr from Ranipet Commercial Tax Dept (FY2022-23 output/input tax mismatches)Management expects insignificant impact
4 Aug 2026Q1 FY27: revenue INR 546.7 Cr (+21.5% YoY), EBITDA INR 35.9 Cr, PAT INR -43.67 Cr; standalone PAT INR +14.2 Cr; board approves up to INR 750 Cr fund-raise and windmill saleOperating recovery; liquidity gap disclosed (current liabilities exceed current assets by INR 742 Cr)
5 Aug 2026Anti-dumping duty on PAN from China (USD 40.08/MT) and Korea (USD 140.17/MT) continued for five yearsKey protection for Indian PAN spread
7 Aug 202653rd AGM: FY26 accounts adopted; Ramya Bharathram re-appointed; PKF Sridhar & Santhanam appointed auditorGovernance
13 Aug 2026ICRA downgrade to [ICRA]BBB (Negative)/A3+; US cost to USD 340 m; full commissioning Dec 2026; FY26 covenant breaches waivedMost material negative development of the period
19 Aug 2026Second tax matter
28 Aug 2026Reports of INR 400–500 Cr plan (INR 200–250 Cr preferential issue, OOSB sale, possible UPL stake sale); Walker Chandiok resigns as TCLIPL auditor (group harmonisation, no concerns cited)Capital-raising pathway
30 Aug 2026Fund Raising Committee meeting outcome filed–
Aug–Sep 2026Stock hits 52-week lows (~INR 143–144)Market scepticism
7 Oct 2026Share price INR 147.70; market cap ~INR 1,781 Cr; 52-week change -49.6%Current state
~3 Nov 2026 (expected)Q2 FY27 results (S&P estimated date)Next catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment: Organic chemicals segment revenue fell from INR 20,831 Mn in FY2024 to INR 17,355 Mn in FY2026.
Thirumalai Chemicals Limited — Revenue by Segment
Series (INR Mn)FY2024FY2025FY2026
Organic chemicals segment revenue20,83120,49517,355
Segment pre-tax result-350-410-2,020

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Thirumalai Chemicals Ltd, FY2025-26 Integrated Annual Report and 53rd AGM Notice (NSE filing, 11 Jul 2026)
  2. Thirumalai Chemicals Ltd exchange filings: preferential issue outcomes (26 Aug 2025; 29 Oct 2025; 23 Dec 2025) · US subsidiary press releases (Dec 2025; 2 Jan 2026); board outcome 14 Feb 2026 · Reg. 32 statements (30 May 2026; 4 Aug 2026); credit rating intimation (13 Aug 2026); promoter group list (8 Apr 2026); results filings Oct 2018 and Jul 2024 (segment note)
  3. ICRA rating rationales: 3 Dec 2024; 27 May 2025; 26 Aug 2025; 25 Nov 2025; 12 Jan 2026; 9 Jun 2026; 13 Aug 2026
  4. Ministry of Finance, Customs (ADD) Notification 20/2026, 5 Aug 2026: DGTR final findings 7 May 2026
  5. S&P Global Market Intelligence data via StockAnalysis.com (income statement, balance sheet, cash flow, ratios, statistics; accessed Oct 2026)
  6. Screener.in (standalone financial history and announcements)
  7. I G Petrochemicals Ltd Q4 FY26 investor communication (21 May 2026)
  8. Indian Chemical News (Feb 2025: Dec 2025) · Lubes'n'Greases (Jan 2022) · Business Standard (24 Dec 2025) · MarketsMojo, ScanX, Univest, Sahi, FilingReader, Tijori, Kotak Securities, Upstox, Trendlyne, IIFL, Anand Rathi, Fyers (2025–2026)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.